Evaluation of the Duration of Anti-Tuberculosis Drug Administration on Leukocyte Profiles in Tuberculosis Patients
DOI:
https://doi.org/10.35916/thmr.v7i1.129Keywords:
Anti-tuberculosis drugs, leukocyte profile, tuberculosisAbstract
Tuberculosis (TB) is a global health problem that requires monitoring the immune response during treatment. Leukocyte profile is an important indicator in assessing the body's response to anti-tuberculosis drug therapy. The purpose of the study was to determine the difference in leukocyte profiles in pulmonary TB patients after 0 months and 2 months of anti-tuberculosis drug treatment—analytical research method with cross-sectional design on 60 pulmonary TB patients in Sungai Malang and Karias Health Center. Samples were selected purposively. Leukocyte examination was performed using Hematology Analyzer, and data were analyzed by independent t-test and Mann-Whitney. The results showed a significant decrease in the number of leukocytes (9,877/mm³ to 6,678/mm³, p<0.05), segment neutrophils (68.73% to 51.33%, p<0.05), and a significant increase in lymphocytes (21.07% to 37.33%, p<0.05). Basophils, eosinophils, rod neutrophils, and monocytes showed no significant difference (p>0.05). Conclusion A 2-month anti-tuberculosis drug treatment duration decreased leukocytes and segment neutrophils and significantly increased lymphocytes. Leukocyte monitoring is recommended as an indicator of therapy response.
References
Shafee M, Abbas F, Ashraf M, Alammengal M, Kakar N, Ahmad Z. Hematological profile and risk factors associated with pulmonary tuberculosis patients in Quetta, Pakistan. Pak J Med Sci. 2014;30: 36–40
World Health Organization (WHO). Global tuberculosis report. 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023. Accessed 2-16-2025
Bestari G, Adang. Perbedaan jumlah leukosit sebelum dan sesudah pemberian obat anti tuberkulosis pada fase awal. Karya Tulis Ilmiah. Yogyakarta: Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Muhammadiyah Yogyakarta; 2014
Oehadian A. Aspek hematologi tuberkulosis. Bandung: Sub Bagian Hematologi-Onkologi Medik SMF Penyakit Dalam RS Perjan Hasan Sadikin/Fakultas Kedokteran Universitas Padjajaran Bandung; 2003.
Lubis F. Analisa jenis dan jumlah sel leukosit pada penderita tuberculosis. Skripsi. Universitas Medan Area Medan; 2021.
Hairani T. Gambaran jumlah leukosit pada penderita TB paru. Poltekkes Kemenkes RI Medan; 2019.
Sunarmi K, Kurniawaty. Hubungan karakteristik pasien TB paru. J Aisyiyah Medika. 2022;7(2):182-7.
Sutrisna M, Rahmadan E. Hubungan usia dan jenis kelamin dengan TB MDR. J Kesehatan Masyarakat. 2022;1(4): 370-6.
Caroll MW. Frequency of adverse reactions to tuberculosis chemotherapy. Int J Tuberc Lung Dis. 2012;16(7): 961-7.
Ainu’rohmah S, Purwaeni E, Kafesa A. Perbandingan jumlah leukosit pada penderita tuberkulosis sebelum dan sesudah pengobatan obat anti tuberkulosis fase intensif. Jurnal Kesehatan. 2020;10(2): 84-94.
Sutedjo. Mengenal penyakit melalui hasil pemeriksaan laboratorium. Yogyakarta: Amara Books; 2011. p. 31-33
Ulya N, Ariyadi, Nuroini. Hubungan lama pengobatan TB terhadap leukosit. Semarang; 2018.
Tiemessen S, Shalekoff S, Meddows-Taylor DJ, Martin. Anti-tuberculosis treatment and innate immunity. Univ Johannesburg; 2010.
Kaihena M. Propolis sebagai imunostimulator terhadap infeksi TB. 2013.
Wirawan R. Pemeriksaan laboratorium hematologi. Jakarta: FKUI; 2011.
Diana N. Analisa sel monosit pada darah penderita TBC. Skripsi. Universitas Sari Mutiara Indonesia; 2018.
